Effectiveness of RMSSD-Based Adaptive Music Therapy (Skitii) in Reducing Treatment-Related Distress in Head and Neck Cancer Patients: A Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
- 试验地点
- 1
研究概览
简要总结
This randomized controlled trial evaluates the effectiveness of Skitii adaptive music therapy in reducing treatment related distress among head and neck cancer HNC patients undergoing radiotherapy and or chemotherapy. The study will enroll 70 patients 35 intervention 35 control at Yenepoya Medical College Hospital over 4 to 5 months. The intervention uses real time heart rate variability monitoring RMSSD Root Mean Square of Successive Differences to personalize music selection during treatment. The system employs a novel two phase algorithm Phase 1 to 2.5 minutes uses heart rate to predict initial stress state and select appropriate music while RMSSD values are calculated Phase 2 2 5 to 20 minutes uses RMSSD based real time adaptation. The adaptive algorithm learns individual patient responses and excludes ineffective music tracks maintaining RMSSD more than or equal 30ms indicating reduced stress . The control group receives static music therapy without real time adaptation. The primary outcome is reduction in anxiety measured by Hospital Anxiety and Depression Scale HADS at 3 weeks. Secondary outcomes include depression quality of life treatment adherence HRV parameters and blood cortisol levels. This minimal risk intervention addresses a critical gap in supportive cancer care with 65 to 85 percentage of HNC patients experiencing significant treatment related distress.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)(—)
- 性别
- All
入选标准
- •Demographic: More than 18 years and less than 75 years Able to provide written informed consent Able to understand and communicate in Kannada, English, Hindi, or Malayalam Willing to participate for full study duration 3-6 weeks Medical: Confirmed diagnosis of head and neck cancer any subsite: oral cavity, oropharynx, hypopharynx, larynx, nasopharynx Any cancer stage I to IV Treatment status any of the following Newly diagnosed starting radiotherapy or chemotherapy Currently undergoing radiotherapy and or chemotherapy Pre-operative with neoadjuvant treatment Post-operative undergoing adjuvant therapy Scheduled for minimum 3 weeks of continuous treatment ECOG Performance Status 0 to 2 Life expectancy more than 3 months Baseline distress score more than or equal to 4 on NCCN Distress Thermometer OR HADS anxiety or depression subscale score more than 8 Technical: Able to use smartphone or tablet with assistance No severe hearing impairment preventing headphone use Willing to wear heart rate monitoring device chest strap No known allergy to device materials silicone, fabric, plastic Access to reliable mobile phone for authentication.
排除标准
- •1 Medical Cardiac conditions: Active arrhythmias requiring medication Recent myocardial infarction less than 3 months Severe heart failure NYHA Class III-IV Implanted cardiac pacemaker or defibrillator Atrial fibrillation affecting HRV measurement 2 Neurological/Psychiatric: Severe cognitive impairment MMSE less than 20 Active psychotic disorder requiring hospitalization Severe depression with suicidal ideation HADS more than 15 Uncontrolled epilepsy 3 Treatment-related: Concurrent enrollment in other interventional trials Palliative care without curative-intent treatment 4 Contraindications to HRV monitoring Conditions causing unreliable heart rate monitoring Pregnancy physiological HRV changes Technical: Severe bilateral hearing loss preventing headphone use Documented allergies to device materials Skin conditions at monitoring site preventing device placement Severe chest wall deformities preventing electrode contact Inability to maintain device connection Logistical Geographic inaccessibility preventing regular visits Planned treatment transfer within study period Inability to attend scheduled assessments Language barriers preventing proper consent Unwillingness to comply with daily sessions 3 times per day.
研究者
Dr Prabha Adhikari MR
Yenepoya Medical College Hospital
